Substantial recent advances in DNA sequencing and additional genomic technologies have played a major role in the elucidation of many of the genetic mechanisms of acquired drug resistance ...

[11] The small G protein RAS, the protein kinase RAF, and PI3K have central roles as intracellular mediators of EGFR signaling (Fig. 1) Overexpression of EGFR may be detected in up to 90% of ...

The FDA will decide on new drugs for rosacea, AADC deficiency, breast cancer, transthyretin amyloid cardiomyopathy, and biliary tract cancer.

Pacylex was recognized as BioAlberta's 2024 Company of the Year. The award acknowledges a company that has shown significant achievement within the marketplace and Alberta's business community through ...

Information on the expression of estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2 (HER2), as well as ... and abemaciclib, the PI3 kinase inhibitor alpelisib, ...

Signal transduction mechanism of EGFR (epidermal growth factor receptor ... heparin-binding EGF-like growth factor; PI3K, phosphoinositide 3-kinase; p70S6K, p70 S6 kinase; PTK, protein tyrosine kinase ...

Inavolisib is a small molecule commercialized by Roche, with a leading Pre-Registration program in Human Epidermal Growth Factor Receptor 2 Negative Breast ... It acts by targeting ...

In a series of studies based on breast cancer cells, ICT reduced the expression of ER- α36, a key protein responsible for the development of triple-negative breast cancer (TNBC), as well as the ...

It acts by targeting isoforms of phosphoinositide 3-kinase (PI3K alpha/delta ... anaplastic large cell lymphoma (ALCL), metastatic breast cancer, human epidermal growth factor receptor 2 negative ...

In first-line metastatic NSCLC patients with EGFR PACC mutations, the overall response rate by blinded independent central review was 81.8% (n=22; 95% CI, 59.7–94.8%) for those receiving the 240 ...